Novel Developments in Lung and Gut Microbiota and Their Cross-talk with the Development of Chronic Obstructive Pulmonary Disease

doi:10.12114/j.issn.1007-9572.2022.0539

Abstract

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that greatly threatens human health. Studies have found that compared with the healthy population, the mucosal barrier function and immune homeostasis in COPD patients are impaired due to significantly changed composition and structure of both lung and gut microbiota, which further aggravate the disease progression. Taking measures to actively improve the microbial balance in lung and gut microbiota is very important for the prevention and delaying of the development of COPD. However, the summary and understanding of the role of lung and gut microbiota and their cross-talk mechanism in COPD still have much room for development. We reviewed the latest developments in the composition characteristics of lung and gut microbiota and the possible cross-talk mechanism between them in healthy people and COPD patients, as well as the prevention and treatment of COPD based on lung and gut microbiota and their cross-talk, providing new ideas for pathogenesis exploration, early diagnosis, prevention and treatment of COPD.

Key words: Pulmonary disease, chronic obstructive, Lung-gut axis, Lung microbiota, Gut microbiota, Microbial interactions, Diagnosis, Prevention, Review

摘要：

慢性阻塞性肺疾病（COPD）是一种常见的慢性呼吸系统疾病，对人类健康造成极大威胁。研究发现，COPD患者与健康人群相比，肺部菌群及肠道菌群的组成结构发生了显著改变，导致黏膜屏障功能及机体免疫稳态被破坏，进而加重病情。积极调节肺部、肠道菌群平衡对于干预COPD的发生、发展有着至关重要的作用，但目前关于肺部、肠道菌群及其相互作用机制在COPD中作用的总结和认识还有待进一步阐明。本文就健康人群以及COPD患者肺部、肠道菌群的组成特点及可能的相互作用机制，以及现阶段基于肺部、肠道菌群及其相互作用防治COPD的最新研究成果进行综述，以期为COPD的发病机制、早期诊断、预防与治疗研究提供新思路。

关键词: 肺疾病，慢性阻塞性, 肺-肠轴, 肺部菌群, 肠道菌群, 微生物相互作用, 诊断, 预防, 综述

SHEN Junxi,ZHU Xing,CHEN Yunzhi, et al. Novel Developments in Lung and Gut Microbiota and Their Cross-talk with the Development of Chronic Obstructive Pulmonary Disease[J]. Chinese General Practice, 2023, 26(20): 2548-2554. DOI: 10.12114/j.issn.1007-9572.2022.0539.
沈俊希,朱星,陈云志等. 肺部、肠道菌群及其相互作用与慢性阻塞性肺疾病发生发展的研究进展[J]. 中国全科医学, 2023, 26(20): 2548-2554. DOI: 10.12114/j.issn.1007-9572.2022.0539.

Figures/Tables 1

References 66

[1]	ADELOYE D, AGARWAL D, BARNES P J，et al. Research priorities to address the global burden of chronic obstructive pulmonary disease （COPD） in the next decade[J]. J Glob Health，2021，11:15003. DOI：10.7189/jogh.11.15003.
[2]	Gbd Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med，2020，8(6):585-596. DOI：10.1016/S2213-2600(20)30105-3.
[3]	WANG C, XU J Y, YANG L，et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China （the China Pulmonary Health[CPH]study）：a national cross-sectional study[J]. Lancet，2018，391(10131):1706-1717. DOI：10.1016/S0140-6736(18)30841-9.
[4]	LIU W, WANG W, LIU J M，et al. Trend of mortality and years of life lost due to chronic obstructive pulmonary disease in China and its provinces，2005-2020[J]. Int J Chron Obstruct Pulmon Dis，2021，16:2973-2981. DOI：10.2147/COPD.S330792.
[5]	WU Y, SONG P, LIN S，et al. Global burden of respiratory diseases attributable to ambient particulate matter pollution：findings from the global burden of disease study 2019[J]. Front Public Health，2021，9:740800. DOI：10.3389/fpubh.2021.740800.
[6]	MKOROMBINDO T, TRAN-NGUYEN T K, YUAN K Y，et al. HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk[J]. JCI Insight，2021，6(19):e150187. DOI：10.1172/jci.insight.150187.
[7]	ESPIRITO SANTO C, CASEIRO C, MARTINS M J，et al. Gut microbiota，in the halfway between nutrition and lung function[J]. Nutrients，2021，13(5):1716. DOI：10.3390/nu13051716.
[8]	CHARLSON E S, BITTINGER K, HAAS A R，et al. Topographical continuity of bacterial populations in the healthy human respiratory tract[J]. Am J Respir Crit Care Med，2011，184(8):957-963. DOI：10.1164/rccm.201104-0655OC.
[9]	BUDDEN K F, GELLATLY S L, WOOD D L，et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol，2017，15(1):55-63. DOI：10.1038/nrmicro.2016.142.
[10]	VENKATARAMAN A, BASSIS C M, BECK J M，et al. Application of a neutral community model to assess structuring of the human lung microbiome[J]. Mbio，2015，6(1):e02284-02214. DOI：10.1128/mBio.02284-14.
[11]	BASSIS C M, ERB-DOWNWARD J R, DICKSON R P，et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals[J]. mBio，2015，6(2):e00037. DOI：10.1128/mBio.00037-15.
[12]	HILTY M, BURKE C, PEDRO H，et al. Disordered microbial communities in asthmatic airways[J]. PLoS One，2010，5(1):e8578. DOI：10.1371/journal.pone.0008578.
[13]	BECK J M, YOUNG V B, HUFFNAGLE G B. The microbiome of the lung[J]. Transl Res，2012，160(4):258-266. DOI：10.1016/j.trsl.2012.02.005.
[14]	NIELSEN R, XUE Y X, JONASSEN I，et al. Repeated bronchoscopy in health and obstructive lung disease：is the airway microbiome stable?[J]. BMC Pulm Med，2021，21(1):342. DOI：10.1186/s12890-021-01687-0.
[15]	KNUDSEN K S, LEHMANN S, NIELSEN R，et al. The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease[J]. PLoS One，2022，17(1):e0262082. DOI：10.1371/journal.pone.0262082.
[16]	WANG Z, BAFADHEL M, HALDAR K，et al. Lung microbiome dynamics in COPD exacerbations[J]. Eur Respir J，2016，47(4):1082-1092. DOI：10.1183/13993003.01406-2015.
[17]	LEUNG J M, TIEW P Y, MAC AOG?IN M，et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD[J]. Respirology，2017，22(4):634-650. DOI：10.1111/resp.13032.
[18]	MAYHEW D, DEVOS N, LAMBERT C，et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations[J]. Thorax，2018，73(5):422-430. DOI：10.1136/thoraxjnl-2017-210408.
[19]	PRAGMAN A A, KNUTSON K A, GOULD T J，et al. Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype：a case-control observational study[J]. Respir Res，2019，20(1):114. DOI：10.1186/s12931-019-1080-4.
[20]	ZHU W X, WU Y L, LIU H，et al. Gut-lung axis：microbial crosstalk in pediatric respiratory tract infections[J]. Front Immunol，2021，12:741233. DOI：10.3389/fimmu.2021.741233.
[21]	ARUMUGAM M, RAES J, PELLETIER E，et al. Enterotypes of the human gut microbiome[J]. Nature，2011，473(7346):174-180. DOI：10.1038/nature09944.
[22]	EL MOUZAN M, AL-HUSSAINI A A, AL SARKHY A，et al. Intestinal microbiota profile in healthy Saudi children：the bacterial domain[J]. Saudi J Gastroenterol，2022，28(4):312-317. DOI：10.4103/sjg.sjg_585_21.
[23]	ABDULLAH B, DAUD S, AAZMI M S，et al. Gut microbiota in pregnant Malaysian women：a comparison between trimesters，body mass index and gestational diabetes status[J]. BMC Pregnancy Childbirth，2022，22(1):152. DOI：10.1186/s12884-022-04472-x.
[24]	TANG Q, JIN G, WANG G，et al. Current sampling methods for gut microbiota：a call for more precise devices[J]. Front Cell Infect Microbiol，2020，10:151. DOI：10.3389/fcimb.2020.00151.
[25]	ANANYA F N, AHAMMED M R, FAHEM M M，et al. Association of intestinal microbial dysbiosis with chronic obstructive pulmonary disease[J]. Cureus，2021，13(11):e19343. DOI：10.7759/cureus.19343.
[26]	SUN Z, ZHU Q L, SHEN Y，et al. Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations[J]. Kaohsiung J Med Sci，2020，36(2):107-113. DOI：10.1002/kjm2.12147.
[27]	BOWERMAN K L, REHMAN S F, VAUGHAN A，et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease[J]. Nat Commun，2020，11(1):5886. DOI：10.1038/s41467-020-19701-0.
[28]	LI N J, DAI Z L, WANG Z，et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease[J]. Respir Res，2021，22(1):274. DOI：10.1186/s12931-021-01872-z.
[29]	邓素敏，朱涛峰，陈如华，等.慢性阻塞性肺疾病稳定期患者肠道菌群状态与炎性指标及肺功能的相关性分析[J].中国全科医学，2020，23(17):2137-2141. DOI：10.12114/j.issn.1007-9572.2019.00.644.
[30]	吴永红，陈军，罗洲.慢性阻塞性肺疾病肠道微生态与炎症因子及临床指标的相关性[J].实用医学杂志，2020，36(5):634-638,644. DOI：10.3969/j.issn.1006?5725.2020.05.018.
[31]	ESPIRITO SANTO C, CASEIRO C, MARTINS M J，et al. Gut microbiota，in the halfway between nutrition and lung function[J]. Nutrients，2021，13(5):1716. DOI：10.3390/nu13051716.
[32]	BINGULA R, FILAIRE M, RADOSEVIC-ROBIN N，et al. Desired turbulence? Gut-lung axis，immunity，and lung cancer[J]. J Oncol，2017，2017:5035371. DOI：10.1155/2017/5035371.
[33]	DICKSON R P, SINGER B H, NEWSTEAD M W，et al. Enrichment of the lung microbiome with gut bacteria in Sepsis and the acute respiratory distress syndrome[J]. Nat Microbiol，2016，1(10):16113. DOI：10.1038/nmicrobiol.2016.113.
[34]	MCALEER J P, NGUYEN N L, CHEN K，et al. Pulmonary Th17 antifungal immunity is regulated by the gut microbiome[J]. J Immunol，2016，197(1):97-107. DOI：10.4049/jimmunol.1502566.
[35]	PERRONE E E, JUNG E, BREED E，et al. Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis[J]. Shock，2012，38(1):68-75. DOI：10.1097/SHK.0b013e318259abdb.
[36]	SZE M A, TSURUTA M, YANG S W，et al. Changes in the bacterial microbiota in gut，blood，and lungs following acute LPS instillation into mice lungs[J]. PLoS One，2014，9(10):e111228. DOI：10.1371/journal.pone.0111228.
[37]	肖锶瑶，张纾难.肠道菌群和呼吸系统疾病相关性的研究进展[J].中国全科医学，2021，24(9):1165-1172. DOI：10.12114/j.issn.1007-9572.2021.00.003.
[38]	STEFAN K L, KIM M V, IWASAKI A，et al. Commensal microbiota modulation of natural resistance to virus infection[J]. Cell，2020，183(5):1312-1324.e10. DOI：10.1016/j.cell.2020.10.047.
[39]	PU Q Q, LIN P, GAO P，et al. Gut microbiota regulate gut-lung axis inflammatory responses by mediating ILC2 compartmental migration[J]. J Immunol，2021，207(1):257-267. DOI：10.4049/jimmunol.2001304.
[40]	WANG J, LI F Q, WEI H M，et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation[J]. J Exp Med，2014，211(12):2397-2410. DOI：10.1084/jem.20140625.
[41]	ICHINOHE T, PANG I K, KUMAMOTO Y，et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection[J]. Proc Natl Acad Sci USA，2011，108(13):5354-5359. DOI：10.1073/pnas.1019378108.
[42]	PAGE M J, KELL D B, PRETORIUS E. The role of lipopolysaccharide-induced cell signalling in chronic inflammation[J]. Chronic Stress （Thousand Oaks），2022，6:24705470221076390. DOI：10.1177/24705470221076390.
[43]	LIU Y R, KUANG D, LI D，et al. Roles of the gut microbiota in severe SARS-CoV-2 infection[J]. Cytokine Growth Factor Rev，2022，63:98-107. DOI：10.1016/j.cytogfr.2022.01.007.
[44]	DABROWSKI A N, SHRIVASTAV A, CONRAD C，et al. Peptidoglycan recognition protein 4 limits bacterial clearance and inflammation in lungs by control of the gut microbiota[J]. Front Immunol，2019，10:2106. DOI：10.3389/fimmu.2019.02106.
[45]	BLANCO-PEREZ F, STEIGERWALD H, SCHULKE S，et al. The dietary fiber pectin：health benefits and potential for the treatment of allergies by modulation of gut microbiota[J]. Curr Allergy Asthma Rep，2021，21(10):43. DOI：10.1007/s11882-021-01020-z.
[46]	ANTUNES K H, STEIN R T, FRANCESCHINA C，et al. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis[J]. EBio Medicine，2022，77:103891. DOI：10.1016/j.ebiom.2022.103891.
[47]	CHEN Z Y, XIAO H W, DONG J L，et al. Gut microbiota-derived PGF2α fights against radiation-induced lung toxicity through the MAPK/NF-κB pathway[J]. Antioxidants （Basel），2021，11(1):65. DOI：10.3390/antiox11010065.
[48]	DANIEL N, NACHBAR R T, TRAN T T T，et al. Gut microbiota and fermentation-derived branched chain hydroxy acids mediate health benefits of yogurt consumption in obese mice[J]. Nat Commun，2022，13(1):1343. DOI：10.1038/s41467-022-29005-0.
[49]	NEGATU D A, GENGENBACHER M, DARTOIS V，et al. Indole propionic acid，an unusual antibiotic produced by the gut microbiota，with anti-inflammatory and antioxidant properties[J]. Front Microbiol，2020，11:575586. DOI：10.3389/fmicb.2020.575586.
[50]	CHEN Z Y, WANG B, DONG J L，et al. Gut microbiota-derived l-histidine/imidazole propionate axis fights against the radiation-induced cardiopulmonary injury[J]. Int J Mol Sci，2021，22(21):11436. DOI：10.3390/ijms222111436.
[51]	TIAN X L, HELLMAN J, HORSWILL A R，et al. Elevated gut microbiome-derived propionate levels are associated with reduced sterile lung inflammation and bacterial immunity in mice[J]. Front Microbiol，2019，10:159. DOI：10.3389/fmicb.2019.00159.
[52]	LIU Q, TIAN X L, MARUYAMA D，et al. Lung immune tone via gut-lung axis：gut-derived LPS and short-chain fatty acids' immunometabolic regulation of lung IL-1β，FFAR2，and FFAR3 expression[J]. Am J Physiol Lung Cell Mol Physiol，2021，321(1):L65-78. DOI：10.1152/ajplung.00421.2020.
[53]	KAGEYAMA Y, NISHIZAKI Y, AIDA K，et al. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19：a single-arm，double-blind，prospective trial combined with an in vitro cytokine response assay[J]. Exp Ther Med，2022，23(1):20. DOI：10.3892/etm.2021.10942.
[54]	JAMALKANDI S A, AHMADI A, AHRARI I，et al. Oral and nasal probiotic administration for the prevention and alleviation of allergic diseases，asthma and chronic obstructive pulmonary disease[J]. Nutr Res Rev，2021，34(1):1-16. DOI：10.1017/S0954422420000116.
[55]	VAN DEN BROEK M F L, DE BOECK I, CLAES I J J，et al. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis[J]. Benef Microbes，2018，9(3):429-439. DOI：10.3920/BM2017.0101.
[56]	张梦洁，唐继红.口服益生菌对慢性阻塞性肺病患者肠道菌群和肺功能及预后的影响[J].中国微生态学杂志，2021，33(7):803-805,809. DOI：10.13381/j.cnki.cjm.202107011.
[57]	胡银霞，范忠杰，张丽.双歧杆菌四联活菌片联合肠内营养对慢性阻塞性肺疾病合并呼吸衰竭患者的临床疗效[J].中国微生态学杂志，2021，33(1):58-61. DOI：10.13381/j.cnki.cjm.202101010.
[58]	CARVALHO J L, MIRANDA M, FIALHO A K，et al. Oral feeding with probiotic Lactobacillus rhamnosus attenuates cigarette smoke-induced COPD in C57Bl/6 mice：relevance to inflammatory markers in human bronchial epithelial cells[J]. PLoS One，2020，15(4):e0225560. DOI：10.1371/journal.pone.0225560.
[59]	JANG Y O, LEE S H, CHOI J J，et al. Fecal microbial transplantation and a high fiber diet attenuates emphysema development by suppressing inflammation and apoptosis[J]. Exp Mol Med，2020，52(7):1128-1139. DOI：10.1038/s12276-020-0469-y.
[60]	TROMPETTE A, GOLLWITZER E S, YADAVA K，et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis[J]. Nat Med，2014，20(2):159-166. DOI：10.1038/nm.3444.
[61]	BLANCO-PEREZ F, STEIGERWALD H, SCHULKE S，et al. The dietary fiber pectin：health benefits and potential for the treatment of allergies by modulation of gut microbiota[J]. Curr Allergy Asthma Rep，2021，21(10):43. DOI：10.1007/s11882-021-01020-z.
[62]	JANG Y O, KIM O H, KIM S J，et al. High-fiber diets attenuate emphysema development via modulation of gut microbiota and metabolism[J]. Sci Rep，2021，11(1):7008. DOI：10.1038/s41598-021-86404-x.
[63]	SZMIDT M K, KALUZA J, HARRIS H R，et al. Long-term dietary fiber intake and risk of chronic obstructive pulmonary disease：a prospective cohort study of women[J]. Eur J Nutr，2020，59(5):1869-1879. DOI：10.1007/s00394-019-02038-w.
[64]	YONG W X, ZHANG L Y, CHEN Y X，et al. Jianpi Huatan Tongfu Granule alleviates inflammation and improves intestinal flora in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. J Int Med Res，2020，48(4):300060520909235. DOI：10.1177/0300060520909235.
[65]	JIAO J, TANG Q, WANG T J，et al. The therapeutic effect of Xuanbai Chengqi Decoction on chronic obstructive pulmonary disease with excessive heat in the lung and fu-organs based on gut and lung microbiota as well as metabolic profiles[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2022，1198:123250. DOI：10.1016/j.jchromb.2022.123250.
[66]	WANG Y A, LI N, LI Q Y，et al. Xuanbai Chengqi Decoction ameliorates pulmonary inflammation via reshaping gut microbiota and rectifying Th17/treg imbalance in a murine model of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis，2021，16:3317-3335. DOI：10.2147/COPD.S337181.

菌群部位	健康人群	COPD患者
肺部菌群	门水平：以厚壁菌门、拟杆菌门和变形菌门等为主^[12,13]	门水平：以厚壁菌门、拟杆菌门和变形菌门等为主，但变形菌门丰度增加^[15]
	属水平：以拟杆菌属、普雷沃菌属、假单胞菌属、韦荣球菌属、链球菌属、奈瑟菌属、嗜血杆菌属和梭杆菌属等为主^[12,13]	属水平：链球菌属、罗斯菌属、韦荣球菌属、普雷沃菌属和嗜血杆菌属丰度增加^[14,15]，乳酸杆菌属丰度减少^[18]。随着疾病严重程度增加普雷沃菌属、韦荣球菌属逐渐减少^[18]
肠道菌群	门水平：以厚壁菌门、拟杆菌门、放线菌门、变形菌门、疣微菌门和梭杆菌门为主^[21]	门水平：以厚壁菌门、拟杆菌门、变形菌门、放线菌门和疣微菌门为主^[26]。Ⅲ~Ⅳ期患者出现拟杆菌门减少^[28]
	属水平：以粪杆菌属、双歧杆菌属、拟杆菌属、布劳菌属等为主^[22,23]	属水平：Ⅰ期患者以Tyzzerella 4和戴阿利斯特杆菌属减少；Ⅱ~Ⅳ期以蓝绿藻菌属减少；Ⅲ~Ⅳ期患者梭杆菌属和气球菌属增加^[28]

菌群部位	健康人群	COPD患者
肺部菌群	门水平：以厚壁菌门、拟杆菌门和变形菌门等为主^[12,13]	门水平：以厚壁菌门、拟杆菌门和变形菌门等为主，但变形菌门丰度增加^[15]
	属水平：以拟杆菌属、普雷沃菌属、假单胞菌属、韦荣球菌属、链球菌属、奈瑟菌属、嗜血杆菌属和梭杆菌属等为主^[12,13]	属水平：链球菌属、罗斯菌属、韦荣球菌属、普雷沃菌属和嗜血杆菌属丰度增加^[14,15]，乳酸杆菌属丰度减少^[18]。随着疾病严重程度增加普雷沃菌属、韦荣球菌属逐渐减少^[18]
肠道菌群	门水平：以厚壁菌门、拟杆菌门、放线菌门、变形菌门、疣微菌门和梭杆菌门为主^[21]	门水平：以厚壁菌门、拟杆菌门、变形菌门、放线菌门和疣微菌门为主^[26]。Ⅲ~Ⅳ期患者出现拟杆菌门减少^[28]
	属水平：以粪杆菌属、双歧杆菌属、拟杆菌属、布劳菌属等为主^[22,23]	属水平：Ⅰ期患者以Tyzzerella 4和戴阿利斯特杆菌属减少；Ⅱ~Ⅳ期以蓝绿藻菌属减少；Ⅲ~Ⅳ期患者梭杆菌属和气球菌属增加^[28]